Ravi Misra

“So, just on the neurobusiness and Cincinnati, when you talk about return to manufacturing, how should we kind of put that in the context of revenue?”

“So just on the revenue guide, so can you maybe talk about what gets you to the high end or the low end of the 3Q guide? And, you know, while we're at it, 2027 kind of consensus has growth acceleration on the top line.”

“So, first, just on PMA timing in breast recon and just kind of commercialization prospects, assuming you get those, could you provide some more detail? And then I have a follow-up.”

“Just maybe a philosophical question here. Good morning. Good evening. I'd love to understand the thinking at the company around how you're balancing this 11% to 13% growth outlook amidst what appears to be a pretty significant product cycle.”

“First, just on the free cash flow generation and improvement, it's a little bit weaker than I think we thought what we were looking for in kind of the prior expectations.”